Segment and Geographical Information

9 Months Ended

Jun. 30, 2018

15. Segment and Geographical Information

The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

The tables below present segment revenue, operating (loss) income and depreciation and amortization, as follows:

	Three Months Ended						Nine Months Ended
	June 30,						June 30,
(Dollars in thousands)	2018			2017			2018			2017
Revenue:
Medical Device	$	16,701		$	12,778		$	43,527		$	39,260
In Vitro Diagnostics		5,526			5,012			14,771			13,794
Total revenue	$	22,227		$	17,790		$	58,298		$	53,054

Operating (loss) income:
Medical Device	$	(6,193	)	$	1,403		$	(6,351	)	$	6,627
In Vitro Diagnostics		2,176			2,230			6,269			5,922
Total segment operating (loss) income		(4,017	)		3,633			(82	)		12,549
Corporate		(2,233	)		(1,890	)		(6,277	)		(5,861	)
Total operating (loss) income	$	(6,250	)	$	1,743		$	(6,359	)	$	6,688

Depreciation and amortization:
Medical Device	$	1,333		$	1,132		$	3,929		$	3,180
In Vitro Diagnostics		101			103			291			309
Corporate		171			170			491			517
Total depreciation and amortization	$	1,605		$	1,405		$	4,711		$	4,006

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision-making process.